CRYBG1 (crystallin beta-gamma domain containing 1) is a gene located on chromosome 6 with emerging roles in immune regulation and disease pathogenesis. Primary Function: CRYBG1 functions as a potential tumor suppressor, possibly through interactions with the cytoskeleton [UniProt annotation]. Mechanism: Recent integrated bioinformatics and experimental studies identified CRYBG1 as a hub gene associated with neutrophil extracellular trap (NET) formation in rheumatoid arthritis, with high expression detected in synovial and neutrophilic cells 1. Additionally, CRYBG1 was expressed at elevated levels in extranodal NK/T-cell lymphoma cells alongside other tumor suppressor genes, suggesting a potential protective role 2. Disease Relevance: CRYBG1 has been implicated in multiple pathological conditions including rheumatoid arthritis, where it serves as a NET-associated biomarker 1, and appears in fusion transcripts (FGFR2::CRYBG1 and RTN4IP1::CRYBG1) in breast cancer cell lines, indicating potential oncogenic involvement 3. A genetic variant (rs1770731) in CRYBG1 was identified as potentially protective against severe COVID-19 in Brazilian Amazon populations 4. Clinical Significance: CRYBG1 represents a potential diagnostic biomarker and therapeutic target in rheumatoid arthritis and lymphoid malignancies, though further validation is needed to establish its clinical utility.